In this issue:
- Adding ibrutinib to R-CHOP in DLBCL with BCL2-MYC co-expression
- History of idelalisib in indolent non-Hodgkin lymphoma
- Venetoclax and idasanutlin in relapsed/refractory AML
- Dabrafenib + trametinib in relapsed/refractory BRAF V600E HCL
- Atezolizumab + R-CHOP in previously untreated DLBCL
- Ide-cel vs. standard regimens in relapsed/refractory MM
- Optimising lenalidomide maintenance for MM by extended genetic profiling
- Auto vs. allo SCT in primary plasma cell leukaemia
- Impact of time between induction and auto transplant in newly diagnosed MM
- Interventions and outcomes in MM receiving salvage after anti-BCMA CAR T-cells
Please login below to download this issue (PDF)